Year-end Sale % OFF 
Abstract
Dengue virus type 2 from infected human serum has been adapted to DBS-FRhL-2 and WI-38 cells which are candidate substrates for virus vaccine production. Initially, the infected DBS-FRhL-2 monolayers were refed with maintenance medium and were reharvested after prolonged incubation. With WI-38 cells, virus could be recovered only if previously passaged in DBS-FRhL-2 or primary African Green monkey kidney cells. Peak titers of 106 per 0·2 ml were obtained with DBS-FRhL-2 cells whereas maximum titers of 105 per 0·2 ml were obtained with WI-38 cells. After six passages in the two cell strains there appeared to be no attenuation of the virus in terms of mouse neurovirulence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
